Family Medicine
Partner With Us
Advertisement
Conexiant chevron_right Family Medicine chevron_right Allogeneic Islet Transplant Shows Promise Without Immunosuppression
From the Journals

Allogeneic Islet Transplant Shows Promise Without Immunosuppression

First-in-human trial shows genetically engineered islet cells restore insulin secretion in type 1 diabetes without triggering immune rejection.

Conexiant
Full Article Summary Notecard
  1. Genetically engineered islet cells restore insulin production in type 1 diabetes.
  2. Study conducted by Per-Ola Carlsson at Uppsala University.
  3. Utilized CRISPR to inactivate HLA class I and II expression.
  4. 80 million islet cells injected without immunosuppression.
  5. Participant's glycated hemoglobin decreased by ~42%. 

Source: The New England Journal of Medicine

Daily News

Stay up to date with the latest clinical headlines and other information tailored to your specialty.